Advances in Immunotherapy for Glioblastoma Multiforme

Table 1

Stage of clinical development of immunotherapeutics in select cancers.

Cancer type	Mechanism	Agent	Phase
Melanoma	Anti-CTLA-4	Ipilimumab	FDA approved
Melanoma	Anti-PD-1	Nivolumab	Phase III
Melanoma	Anti-PD-1	Pembrolizumab	FDA approved
Melanoma	Adoptive cell therapy		Phases I-II
Melanoma	Peptide Vaccine	Melan-A peptides	Phases I-II
Melanoma	Autologous DC vaccine		Phases I-II
Melanoma	Whole tumor cell vaccine		Phases I-II
NSCLC	Peptide vaccine	EGFR peptide	Phase III
NSCLC	Anti-CTLA-4	Ipilimumab	Phase III
NSCLC	Anti-PD-1	Nivolumab	Phase II